Summarized by Masters of Longevity from PR Newswire.
FDA approved pimicotinib for adults with symptomatic tenosynovial giant cell tumor.
Key Takeaways
- Pimicotinib is an oral CSF‑1R inhibitor approved for adults with TGCT.
- A Phase III trial showed pimicotinib had higher response than placebo.
- Clinical benefits on motion, function, and pain were reported but limited.
